Zymeworks (NYSE:ZYME – Free Report) had its target price upped by Stifel Nicolaus from $20.00 to $21.00 in a report released on Friday, Benzinga reports. The firm currently has a buy rating on the stock.
Other analysts have also issued research reports about the company. Citigroup lowered their target price on Zymeworks from $17.00 to $16.00 and set a buy rating on the stock in a report on Friday, May 3rd. HC Wainwright reissued a neutral rating and set a $10.00 price objective on shares of Zymeworks in a report on Thursday, June 6th. Finally, Wells Fargo & Company lowered their price objective on Zymeworks from $14.00 to $12.00 and set an overweight rating on the stock in a research report on Friday, May 3rd.
Get Our Latest Research Report on ZYME
Zymeworks Trading Down 2.0 %
Zymeworks (NYSE:ZYME – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.01. Zymeworks had a negative net margin of 179.42% and a negative return on equity of 21.52%. The company had revenue of $19.24 million for the quarter, compared to the consensus estimate of $23.16 million. During the same period in the previous year, the business earned ($0.76) EPS. On average, equities research analysts predict that Zymeworks will post -1.24 earnings per share for the current year.
Hedge Funds Weigh In On Zymeworks
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ZYME. AlphaMark Advisors LLC bought a new stake in Zymeworks during the 1st quarter worth approximately $32,000. New York State Teachers Retirement System acquired a new position in Zymeworks in the fourth quarter worth $50,000. AJOVista LLC bought a new stake in shares of Zymeworks during the fourth quarter worth $66,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Zymeworks in the fourth quarter valued at $84,000. Finally, Arizona State Retirement System raised its holdings in shares of Zymeworks by 11.1% in the second quarter. Arizona State Retirement System now owns 12,841 shares of the company’s stock valued at $109,000 after buying an additional 1,285 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.
About Zymeworks
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Recommended Stories
- Five stocks we like better than Zymeworks
- Top Biotech Stocks: Exploring Innovation Opportunities
- From Tokyo to Wall Street: Japan’s Market Impact on U.S. Stocks
- What is the NASDAQ Stock Exchange?
- Arm Holdings: Does the 42% Drop Signal an AI Buying Opportunity?
- Investing in Commodities: What Are They? How to Invest in Them
- Texas Roadhouse Stampedes On EPS Beat as Comp Sales Surge 9.3%
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.